Literature DB >> 36266055

Early Reduction of MRI Activity During 6 Months of Cladribine Tablet Treatment for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.

.   

Abstract

Entities:  

Year:  2022        PMID： 36266055      PMCID： PMC9585483          DOI： 10.1212/NXI.0000000000200061

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN： 2332-7812


× No keyword cloud information.
  1 in total

1.  Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.

Authors:  Nicola de Stefano; Frederik Barkhof; Xavier Montalban; Anat Achiron; Tobias Derfuss; Andrew Chan; Suzanne Hodgkinson; Alexandre Prat; Letizia Leocani; Klaus Schmierer; Finn Sellebjerg; Patrick Vermersch; Heinz Wiendl; Birgit Keller; Sanjeev Roy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-06-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.